Please assess the completion status of the following clinical trial:

Trial Title: Study of NGR-hTNF as Single Agent in Patients Affected by Advanced or Metastatic Malignant Pleural Mesothelioma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients \>18 years affected by malignant pleural mesothelioma previously treated with no more than one systemic therapeutic regimen~* Histologically or cytological confirmed malignant pleural mesothelioma of any of the following subtype: epithelial, sarcomatous, mixed~* Prior intrapleural cytotoxic agents including bleomycin not considered systemic chemotherapy~* ECOG Performance status 0 - 2~* Adequate baseline bone marrow, hepatic and renal function, defined as follows:~  * Neutrophils \> 1.5 x 10\^9/L and platelets \> 100 x 10\^9/L~ * Bilirubin \< 1.5 x ULN~ * AST and/or ALT \< 2.5 x ULN in absence of liver metastasis~ * AST and/or ALT \< 5 x ULN in presence of liver metastasis~ * Serum creatinine \< 1.5 x ULN~* Absence of any conditions in which hypervolemia and its consequences (e.g. increased stroke volume, elevated blood pressure) or haemodilution could represent a risk for the patient (take as reference Technical data sheet human albumin specifically used in Pharmacy Department for NGR-hTNF dilution)~* Patients may have had prior therapy providing the following conditions are met:~  * Chemotherapy and radiotherapy: wash-out period of 28 days~ * Surgery: wash-out period of 14 days~* Normal cardiac function and absence of uncontrolled hypertension~* Patients must give written informed consent to participate in the study~Exclusion Criteria:~* Concurrent anticancer therapy~* Patients may not receive any other investigational agents while on study~* Clinical signs of CNS involvement~* Patients with active or uncontrolled systemic disease/infections or with serious illness or medical conditions, which is incompatible with the protocol~* Known hypersensitivity/allergic reaction to human albumin preparations or to any of the excipients~* Any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol~* Pregnancy or lactation. Patients - both males and females - with reproductive potential (i.e. menopausal for less than 1-year and not surgically sterilized) must practice effective contraceptive measures throughout the study. Women of childbearing potential must provide a negative pregnancy test (serum or urine) within 14 days prior to registration

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- NGR-hTNF (Type: EXPERIMENTAL): NGR-hTNF: 0.8 mcg/m² as 60 minutes intravenous infusion every 3 weeks or weekly

Based on this trial design, predict the completion outcome and termination type (if applicable).